The next generation of sepsis clinical trial designs: What is next after the demise of recombinant human activated protein C?

Critical Care Medicine

Volumn 42, Issue 7, 2014, Pages 1714-1721

  Opal, Steven M ^a   Dellinger, R Phillip ^b   Vincent, Jean Louis ^c   Masur, Henry ^d   Angus, Derek C ^e  

^a BROWN UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c ERASME HOSPITAL   (Belgium)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

clinical trial design; intensive care units; sepsis; septic shock; severe sepsis; tumor necrosis factor antibody

Indexed keywords

DROTRECOGIN; PLACEBO;

ACCURACY; ANTISEPSIS; ARTICLE; CLINICAL EVALUATION; CLINICAL STUDY; EVALUATION STUDY; FOLLOW UP; HUMAN; INTERVENTION STUDY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SEPSIS; STUDY DESIGN;

BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; FIBRINOLYTIC AGENTS; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; RESEARCH DESIGN; SEPSIS;

EID: 84902511727     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000325     Document Type: Article

References (43)

1. Mullard A: Drug withdrawal sends critical care specialists back to basics. Lancet 2011; 378:1769
2. Dellinger RP, Levy MM, Rhodes A, et al: The surviving sepsis guidelines: 2012. Crit Care Med 2013; 41:580-637
3. Cohen J, Calandra T, Opal SM: Sepsis studies need new direction. Lancet Infect Dis 2012; 12:503-505
4. Angus DC: The search for effective therapy for sepsis: Back to the drawing board? JAMA 2011; 306:2614-2615
5. Bernard GR, Vincent JL, Laterre PF, et al: Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
6. Ranieri VM, Thompson BT, Barie PS, et al: Drotrecogin alfa (activated) for adults with septic shock. N Engl J Med 2012; 366:2055-2064
7. McCulloh R, Opal SM: Human recombinant lactoferrin for adult sepsis: Too good to be true? Crit Care Med 2013; 41:908-909
8. Opal SM, Laterre P-F, Francois B, et al: Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis. JAMA 2013; 309:1154-1162
9. Kumar G, Kumar N, Taneja A, et al: Nationwide trends in severe sepsis in the 21st Century (2000-2007). Chest 2011; 140:1223-1231
10. Levy MM, Fink MP, Marshall JC, et al; International Sepsis Definitions Conference: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530-538
11. Angus DC: The lingering consequences of sepsis: The hidden public health disaster? JAMA 2010; 304:1833-1834
12. Iwashyna TJ, Ely EW, Smith DM, et al: Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010; 304:1787-1794
13. Quartin AA, Schein RM, Kett DH, et al: Department of Veterans Affairs Sepsis Cooperative Studies Group. Magnitude and duration of effect of sepsis on survival. JAMA 1997; 277:1058-1063
14. Eidelman LA, Sprung CL: Why have new effective therapies for sepsis not been developed? Crit Care Med 1994; 22:1330-1334
15. Lorente JA, Marshall JC: Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 2005; 24(Suppl 1):107-119
16. Fisher CJ, Agosti J, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996; 334:1697-1702
17. Seok J, Warren HS, Cuenca AG, et al: Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110:3507-3512
18. Girard T, Opal SM, Ely EW: Insights into severe sepsis in older patients: From epidemiology to evidence-based medicine. Clin Infect Dis 2005; 40:719-727
19. Bone RC, Balk RA, Cerra FB, et al; American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655
20. Klein Klouwenberg PM, Ong DS, Bonten MJ, et al: Classification of sepsis, severe sepsis and septic shock: The impact and minor variations in data capture and the definition of SIRS criteria. Intensive Care Med 2012; 38:811-819
21. Vincent JL, Opal SM, Marshall JC, et al: Sepsis definitions: Time for change. Lancet 2013; 381:774-775
22. Lang T: Adaptive trial design: Could we use this approach to improve clinical trials in the field of global health? Am J Trop Med Hyg 2011; 85:967-970
23. Lewis RJ, Viele K, Broglio K, et al: An adaptive, phase II dose finding clinical trial design to evaluate l-carnitine in the treatment of septic shock based upon efficacy and predictive probability of subsequent phase III success. Crit Care Med 2013; 41:1674-1678
24. Macias WL, Vallet B, Bernard GR, et al: Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis. Crit Care Med 2004; 32:2385-2391
25. Fisher CJ, Slotman G, Opal SM, et al: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome. Crit Care Med 1994; 22:12-21
26. Fisher CJ, Dhainaut J-F, Opal SM, et al: Human recombinant interleukin-1 receptor antagonist reduces mortality in sepsis syndrome as a function of disease severity: A randomized, doubleblind, placebo-controlled trial. JAMA 1994; 271:1836-1846
27. Opal SM, Fisher CJ, Pribble JP, et al: The confirmatory interleukin-1 receptor antagonist trial in sepsis: A phase III randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997; 25:1115-1123
28. Bassler D, Briel M, Montori VM, et al; STOPIT-2 Study Group: Stopping randomized trials early for benefit and estimation of treatment effects: Systematic review and meta-regression analysis. JAMA 2010; 303:1180-1187
29. Levy MM, Dellinger RP, Townsend SR, et al: The Surviving Sepsis Campaign: Results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36:222-231
30. Barochia AV, Cui X, Vitberg D, et al: Bundled care for septic shock: An analysis of clinical trials. Crit Care Med 2010; 38: 668-678
31. Abraham E, Laterre PF, Garg R, et al; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-1341
32. Kalil AC, Florescu DF: Severe sepsis: Are PROWESS and PROWESS-SHOCK trials comparable? A clinical and statistical heterogeneity analysis. Crit Care 2013; 17:167
33. Kalil AC, LaRosa SP: Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: A meta-Analysis and metaregression. Lancet Infect Dis 2012; 12:678-686
34. Hall MJ, Williams SN, DeFrances CJ, et al: Inpatient care of septicemia or sepsis: A challenge for patients and hospitals. NCHS Data Brief 2011; 62:1-8
35. Hall MJ, DeFrances CJ, Williams SN et al: National hospital survey: 2007 summary. Natl Health Stat Report 2010; 29:1-24
36. Xiao W, Mindrinros MN, Seok J, et al: A genomic storm in critical injured humans. J Exp Med 2011; 208:2581-2590
37. Boomer JS, To K, Chang KC, et al: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306:2594-2605
38. Rosas-Ballina M, Olofsson PS, Ochani M, et al: Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011; 334:98-101
39. Suffredini AF, Munford RS: Novel therapies for septic shock over the past 4 decades. JAMA 2011; 306:194-199
40. Vincent JL, Ramesh MK, Ernest D, et al: A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013; 41:2069-2079
41. Wu J, Zhou L, Liu J, et al: The efficacy of thymosin alpha 1 for severe sepsis (ETASS): A multicenter, single-blind, randomized and controlled trial. Crit Care 2013; 17:R8
42. Venet F, Foray AP, Villars-Méchin A, et al: IL-7 restores lymphocyte functions in septic patients. J Immunol 2012; 189:5073-5081
43. Jani IV, Peter TF: How point-of-care testing could drive innovation in global health. N Engl J Med 2013; 368:2319-2324